RE: News13 Nov 2023 10:32
Hi Chris,
Agreed, as was stated the Company has been experiencing a commercially challenging period. But focussing on the positives, the sales pipeline has overall values now standing at approximately four times that of six months ago and part of the pipeline growth is attributable to the new strategy to enhance penetration of adjacent markets including Veterinary Medicine, Diagnostics and Research Antibodies. These factors bode well for the Company's future provided opportunities can be progressed and converted into work in progress. And as you know the Company has continued to progress the development of its platform services with AI/ML-AbTM (pronounced "AIM-Lab") being launched. With the stringent cost controls in place combined with the developing pipeline for H2 FY2024, we are working hard to generate a profitable company.
Regards